IL268626B2 - Immunogenic preparations to adjust the immune system and methods to treat bacterial infections in the patient - Google Patents
Immunogenic preparations to adjust the immune system and methods to treat bacterial infections in the patientInfo
- Publication number
- IL268626B2 IL268626B2 IL268626A IL26862619A IL268626B2 IL 268626 B2 IL268626 B2 IL 268626B2 IL 268626 A IL268626 A IL 268626A IL 26862619 A IL26862619 A IL 26862619A IL 268626 B2 IL268626 B2 IL 268626B2
- Authority
- IL
- Israel
- Prior art keywords
- inactivated
- lysate
- equal parts
- salmonella
- beta
- Prior art date
Links
- 208000035143 Bacterial infection Diseases 0.000 title claims 3
- 208000022362 bacterial infectious disease Diseases 0.000 title claims 3
- 238000000034 method Methods 0.000 title claims 3
- 239000000203 mixture Substances 0.000 title claims 2
- 210000000987 immune system Anatomy 0.000 title 1
- 230000002163 immunogen Effects 0.000 title 1
- 239000006166 lysate Substances 0.000 claims 48
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 12
- 241000194017 Streptococcus Species 0.000 claims 12
- 238000000746 purification Methods 0.000 claims 12
- 241001377138 Atlantibacter subterranea Species 0.000 claims 6
- 241000222122 Candida albicans Species 0.000 claims 6
- 241000194032 Enterococcus faecalis Species 0.000 claims 6
- 241000588724 Escherichia coli Species 0.000 claims 6
- 241000186366 Mycobacterium bovis Species 0.000 claims 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 6
- 241000607142 Salmonella Species 0.000 claims 6
- 241000533331 Salmonella bongori Species 0.000 claims 6
- 241001138501 Salmonella enterica Species 0.000 claims 6
- 241000191940 Staphylococcus Species 0.000 claims 6
- 241000191967 Staphylococcus aureus Species 0.000 claims 6
- 241000191963 Staphylococcus epidermidis Species 0.000 claims 6
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 6
- 241000193996 Streptococcus pyogenes Species 0.000 claims 6
- 108010023197 Streptokinase Proteins 0.000 claims 6
- 230000000890 antigenic effect Effects 0.000 claims 6
- 229940095731 candida albicans Drugs 0.000 claims 6
- PYLIXCKOHOHGKQ-UHFFFAOYSA-L disodium;hydrogen phosphate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O PYLIXCKOHOHGKQ-UHFFFAOYSA-L 0.000 claims 6
- 229940032049 enterococcus faecalis Drugs 0.000 claims 6
- 230000000369 enteropathogenic effect Effects 0.000 claims 6
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims 6
- 235000019796 monopotassium phosphate Nutrition 0.000 claims 6
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 6
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 6
- 229960005202 streptokinase Drugs 0.000 claims 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 6
- 230000002195 synergetic effect Effects 0.000 claims 5
- 239000003242 anti bacterial agent Substances 0.000 claims 4
- 229940088710 antibiotic agent Drugs 0.000 claims 4
- 241001480043 Arthrodermataceae Species 0.000 claims 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims 3
- 229930186147 Cephalosporin Natural products 0.000 claims 3
- 241001480036 Epidermophyton floccosum Species 0.000 claims 3
- 241001480037 Microsporum Species 0.000 claims 3
- 241001045770 Trichophyton mentagrophytes Species 0.000 claims 3
- 241000710772 Yellow fever virus Species 0.000 claims 3
- 241000222126 [Candida] glabrata Species 0.000 claims 3
- 230000002238 attenuated effect Effects 0.000 claims 3
- 208000032343 candida glabrata infection Diseases 0.000 claims 3
- 229940124587 cephalosporin Drugs 0.000 claims 3
- 150000001780 cephalosporins Chemical class 0.000 claims 3
- 230000037304 dermatophytes Effects 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 229940127557 pharmaceutical product Drugs 0.000 claims 3
- 229940051021 yellow-fever virus Drugs 0.000 claims 3
- 108010028921 Lipopeptides Proteins 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 229930182555 Penicillin Natural products 0.000 claims 2
- 229940041011 carbapenems Drugs 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 150000002960 penicillins Chemical class 0.000 claims 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims 1
- -1 Carbapenems Chemical class 0.000 claims 1
- 108010015899 Glycopeptides Proteins 0.000 claims 1
- 102000002068 Glycopeptides Human genes 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 239000004098 Tetracycline Substances 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 150000003862 amino acid derivatives Chemical class 0.000 claims 1
- 229940126575 aminoglycoside Drugs 0.000 claims 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 claims 1
- 150000001541 aziridines Chemical class 0.000 claims 1
- 150000001556 benzimidazoles Chemical class 0.000 claims 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims 1
- 229930182483 coumarin glycoside Natural products 0.000 claims 1
- 150000008140 coumarin glycosides Chemical class 0.000 claims 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical class C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 claims 1
- 229940124307 fluoroquinolone Drugs 0.000 claims 1
- 229960002442 glucosamine Drugs 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 150000002460 imidazoles Chemical class 0.000 claims 1
- 230000000899 immune system response Effects 0.000 claims 1
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 1
- 229940041033 macrolides Drugs 0.000 claims 1
- 125000003835 nucleoside group Chemical group 0.000 claims 1
- 150000004291 polyenes Chemical class 0.000 claims 1
- 229920000570 polyether Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 150000003222 pyridines Chemical class 0.000 claims 1
- 150000003230 pyrimidines Chemical class 0.000 claims 1
- 150000007660 quinolones Chemical class 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 235000019364 tetracycline Nutrition 0.000 claims 1
- 150000003522 tetracyclines Chemical class 0.000 claims 1
- 229940040944 tetracyclines Drugs 0.000 claims 1
- 150000003952 β-lactams Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/25—Varicella-zoster virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/431,329 US10213504B2 (en) | 2011-03-18 | 2017-02-13 | Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject |
| PCT/BR2018/000004 WO2018145180A1 (en) | 2017-02-13 | 2018-02-15 | Immunogenic composition for modulating the immune system and methods to treat bacterial infections in a subject |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL268626A IL268626A (en) | 2019-10-31 |
| IL268626B1 IL268626B1 (en) | 2023-12-01 |
| IL268626B2 true IL268626B2 (en) | 2024-04-01 |
Family
ID=63106848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL268626A IL268626B2 (en) | 2017-02-13 | 2018-02-15 | Immunogenic preparations to adjust the immune system and methods to treat bacterial infections in the patient |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3579868A4 (ja) |
| JP (1) | JP2020507629A (ja) |
| KR (1) | KR20190139209A (ja) |
| CN (1) | CN110709099B (ja) |
| AU (1) | AU2018217441A1 (ja) |
| BR (1) | BR112019016670A2 (ja) |
| IL (1) | IL268626B2 (ja) |
| MX (1) | MX2019009689A (ja) |
| RU (1) | RU2019128674A (ja) |
| WO (1) | WO2018145180A1 (ja) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012122618A1 (pt) * | 2011-03-17 | 2012-09-20 | Nowill Alexandre Eduardo | Composição imunogênica para modulação do sistema imune e seu uso, método de tratamento e prevenção de doenças, método para induzir a regeneração celular e método para recondução da resposta imune |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2375180T3 (es) * | 2003-04-30 | 2012-02-27 | Medi Service S.R.L. | Composición inmunomoduladora que contiene una fracción de partículas de lisados bacterianos mecánicos. |
| CA2555253A1 (en) * | 2004-02-06 | 2005-08-25 | Yale University | Compositions of pamps and listeria monocytogenes and methods of use |
| EP2064230A2 (en) * | 2006-08-16 | 2009-06-03 | Novartis AG | Immunogens from uropathogenic escherichia coli |
| EP1938835A1 (en) * | 2006-12-29 | 2008-07-02 | Pevion Biotech AG | Non-specific immunostimulating agents |
| CA2729775A1 (en) * | 2008-07-01 | 2010-01-07 | Emory University | Synergistic induction of humoral and cellular immunity by combinatorial activation of toll-like receptors |
| MX2012000395A (es) * | 2009-07-07 | 2012-02-28 | Novartis Ag | Inmunogenos conservados de escherichia coli. |
| WO2011007257A1 (en) * | 2009-07-16 | 2011-01-20 | Novartis Ag | Detoxified escherichia coli immunogens |
| US8980279B2 (en) * | 2010-07-26 | 2015-03-17 | Qu Biologics | Personalized site-specific immunomodulation |
-
2018
- 2018-02-15 AU AU2018217441A patent/AU2018217441A1/en active Pending
- 2018-02-15 KR KR1020197026857A patent/KR20190139209A/ko not_active Application Discontinuation
- 2018-02-15 BR BR112019016670A patent/BR112019016670A2/pt unknown
- 2018-02-15 JP JP2019564565A patent/JP2020507629A/ja active Pending
- 2018-02-15 IL IL268626A patent/IL268626B2/en unknown
- 2018-02-15 EP EP18751350.2A patent/EP3579868A4/en active Pending
- 2018-02-15 MX MX2019009689A patent/MX2019009689A/es unknown
- 2018-02-15 WO PCT/BR2018/000004 patent/WO2018145180A1/en unknown
- 2018-02-15 RU RU2019128674A patent/RU2019128674A/ru unknown
- 2018-02-15 CN CN201880023729.7A patent/CN110709099B/zh active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012122618A1 (pt) * | 2011-03-17 | 2012-09-20 | Nowill Alexandre Eduardo | Composição imunogênica para modulação do sistema imune e seu uso, método de tratamento e prevenção de doenças, método para induzir a regeneração celular e método para recondução da resposta imune |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019009689A (es) | 2019-12-18 |
| JP2020507629A (ja) | 2020-03-12 |
| CN110709099B (zh) | 2024-03-29 |
| EP3579868A4 (en) | 2021-01-06 |
| BR112019016670A2 (pt) | 2020-04-14 |
| AU2018217441A1 (en) | 2019-10-03 |
| WO2018145180A1 (en) | 2018-08-16 |
| CN110709099A (zh) | 2020-01-17 |
| KR20190139209A (ko) | 2019-12-17 |
| IL268626A (en) | 2019-10-31 |
| EP3579868A1 (en) | 2019-12-18 |
| RU2019128674A3 (ja) | 2021-06-18 |
| RU2019128674A (ru) | 2021-03-16 |
| IL268626B1 (en) | 2023-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Buckley et al. | The AcrAB–TolC efflux system of Salmonella enterica serovar Typhimurium plays a role in pathogenesis | |
| Jeon et al. | Underlying mechanism of antimicrobial activity of chitosan microparticles and implications for the treatment of infectious diseases | |
| Gomes et al. | Control of bovine mastitis: old and recent therapeutic approaches | |
| US9529005B2 (en) | Modulating bacterial MAM polypeptides in pathogenic disease | |
| Zalewska-Piątek et al. | Alternative treatment approaches of urinary tract infections caused by uropathogenic Escherichia coli strains-Review | |
| López et al. | Salmonella Typhimurium general virulence factors: A battle of David against Goliath? | |
| MX2020004420A (es) | Polipeptidos efectores de la subunidad a de la toxina shiga resistentes a la disociacion por proteasa y moleculas dirigidas a las celulas que los comprenden. | |
| Oehlerking et al. | Complete genome sequence of the hemotrophic Mycoplasma suis strain KI3806 | |
| Mosquito et al. | Effect of bovine lactoferrin in Salmonella ser. Typhimurium infection in mice | |
| US9265820B2 (en) | Multivalent vaccine protection from Staphylococcus aureus infection | |
| WO2020039359A3 (en) | Escherichia coli compositions and methods thereof | |
| IL268626B1 (en) | Immunogenic preparations to adjust the immune system and methods to treat bacterial infections in the patient | |
| WO2023004415A3 (en) | Sars-cov-2 vaccine using bacterial spores expressing antigenic fragments | |
| Huy et al. | Intracellular trafficking modulation by ginsenoside Rg3 inhibits Brucella abortus uptake and intracellular survival within RAW 264.7 cells | |
| Yatoo et al. | Emerging antibiotic resistance in Mycoplasma microorganisms, designing effective and novel drugs/therapeutic targets: Current knowledge and futuristic prospects. | |
| Daubenspeck et al. | Identification of exopolysaccharide‐deficient mutants of Mycoplasma pulmonis | |
| Lawrence et al. | Map-based comparative genomic analysis of virulent Haemophilus parasuis serovars 4 and 5 | |
| EP1774975A1 (en) | Use of human lysozyme in preparation of medicine for treating acne | |
| US20190083581A1 (en) | Antibacterial composition containing adk protein as active ingredient, or composition for preventing or treating sepsis | |
| Kappala et al. | Role of different receptors and actin filaments on Salmonella Typhimurium invasion in chicken macrophages | |
| WO2018035046A1 (en) | Treating infections using idsd from proteus mirabilis | |
| Superti et al. | Inv-mediated apoptosis of epithelial cells infected with enteropathogenic Yersinia: a protective effect of lactoferrin | |
| Imran et al. | A Comparative Study of Antimicrobial Profile Having Broad Spectrum Bacteriocins Against Antibiotics | |
| Yang et al. | Inhibition of bacterial swimming by heparin binding of flagellin FliC from Escherichia coli strain Nissle 1917 | |
| Shlla | Investigating the role of Rgg Transcriptional Regulators in Streptococcus pneumoniae |